U.S. Markets close in 1 hr 10 mins

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,768.50+16.50 (+0.35%)
At close: 4:35PM BST
Full screen
Previous Close4,752.00
Open4,778.00
Bid4,740.00 x 6100
Ask4,850.00 x 13000
Day's Range4,765.50 - 4,803.50
52 Week Range3,996.00 - 5,520.00
Volume1,275,123
Avg. Volume2,345,011
Market Cap60.36B
Beta0.63
PE Ratio (TTM)15.64
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.79 (4.51%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • Implied Volatility Surging for AstraZeneca (AZN) Stock Options
    Zacksyesterday

    Implied Volatility Surging for AstraZeneca (AZN) Stock Options

    AstraZeneca (AZN) needs Investors to pay close attention to the stock based on moves in the options market lately.

  • Oncology Space in Focus this Week on ESMO Presentations
    Zacks6 days ago

    Oncology Space in Focus this Week on ESMO Presentations

    There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.

  • Reuters6 days ago

    France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus

    French biotech company Neovacs is confident that its experimental drug to treat lupus could grab significant market share from standard treatments of the auto-immune disease, its chief executive said. About 5 million people globally suffer from some form of lupus, the Lupus foundation of America says, affecting multiple organs and leading to a range of symptoms that can include skin rashes, swollen joints and fevers. Until now, treatments from the likes of GlaxoSmithKline (GSK) and AstraZeneca's MedImmune have focused on the use of monoclonal antibodies, but Neovacs is working on therapeutic vaccines covered by five patent families it calls kinoids, with patent protection until 2032.